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Objective: Mesenchymal stem cells (MSCs) are a promising cell type for the repair of damaged cartilage
in osteoarthritis (OA). However, OA synovial ﬂuid and factors secreted by synovium impede chondro-
genic differentiation of MSCs, and the mechanism responsible for this effect remains unclear. In this
study, we sought to investigate whether M1 and M2 synovial macrophages can contribute to the inhi-
bition of MSC chondrogenesis.
Design: The constitution of synovial macrophage subsets was analysed by immunohistochemical
staining of human OA synovium sections for CD86 (M1 marker) and CD206 (M2 marker). To assess the
effect of synovial macrophages on chondrogenesis, collagen type II (COL2) and aggrecan (ACAN) gene
expression were compared between MSCs undergoing chondrogenic differentiation in medium condi-
tioned (CM) by human OA synovial explants, human synovial macrophages and ﬁbroblasts, or peripheral
blood derived primary human monocytes differentiated towards an M1 or M2 phenotype.
Results: OA synovium contained both M1 and M2 macrophages. Medium conditioned by synovial
macrophages (CD45 þ plastic adherent cells) down-regulated chondrogenic gene expression by MSCs.
Additionally, CM of M1 polarised monocytes signiﬁcantly decreased COL2 and ACAN gene expression by
MSCs; this effect was not observed for treatment with CM of M2 polarised monocytes.
Conclusion: MSC chondrogenesis is inhibited by OA synovium CM through factors secreted by synovial
macrophages and our ﬁndings suggest that M1 polarised subsets are potential mediators of this anti-
chondrogenic effect. Modulation of macrophage phenotype may serve as a beneﬁcial strategy to maxi-
mise the potential of MSCs for efﬁcient cartilage repair.
© 2014 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.: G.J.V.M. Van Osch, Depart-
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The repair of damaged articular cartilage resulting from trauma
or degenerative joint disease poses a major challenge due to the
limited capacity of cartilage for self renewal, attributable to its
avascular nature. Mesenchymal stem cells (MSCs) are considered a
promising cell type for the repair of damaged cartilage due to their
chondrogenic differentiation potential1,2. However, in order to
achieve cartilage repair in vivo, chondrogenically differentiating
MSCs are exposed to inﬂammatorymediators produced in response
to injury or disease. Osteoarthritic synovial ﬂuid and medium
conditioned by synovium explants have been reported to inhibit thetd. All rights reserved.
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destructive inﬂammatory environment, as found in osteoarthritis
(OA), may impede the use of MSCs in cartilage repair strategies.
The synovial membrane is an area of high functional importance
within the joint, responsible for the production of synovial ﬂuid
which lubricates and nourishes chondrocytes. The membrane is
composed of two cell types, synovial macrophages and ﬁbroblasts.
Synovial hyperplasia, increased vascular density and inﬂammatory
cell inﬁltration are common features of OA5. Pro-inﬂammatory fac-
tors from synovial ﬂuid of injured and osteoarthritic joints stimulate
cartilage degradation and inhibit matrix synthesis6e9. Tumour ne-
crosis factor-a (TNF-a), Oncostatin M (OSM), Interleukin (IL)-1b and
IL-6 have been identiﬁed as some of the key players involved in sy-
novial inﬂammation, with synovial macrophages considered to play
a prominent role in the production of these mediators10e13.
Macrophages exhibit a high degree of plasticity, having the
potential to change phenotype according to environmental cues.
They can be categorised as classically activated (M1), representing
pro-inﬂammatory phenotypes, or alternatively activated (M2)
macrophages, encompassingwound healing and regulatory subsets
with anti-inﬂammatory properties14. M1 macrophages are associ-
ated with high production of pro-inﬂammatory mediators such as
TNF-a, IL-6 and IL-12, and cell surface expression of the co-
stimulatory molecule CD86, required for T cell activation and
cytokine production15,16. Macrophages of the M2 subtype produce
immunoregulatory factors including IL-10 and chemokine (CeC
motif) ligand 18 (CCL18), and are associated with the surface
expression of the mannose receptor (CD206)17,18. The M1-
associated cytokines IL-6, IL1b and TNF-a induce destructive pro-
cesses in chondrocytes including down regulation of collagen type
II and aggrecan synthesis, as well as up regulation of matrix
metalloproteinase-9 and cyclooxygenase-2 expression19e23.
We hypothesise that M1 polarised macrophages mediate the
earlier shown anti-chondrogenic effects of OA synovium on MSC
chondrogenesis3. Our ﬁndings highlight a role of synovial macro-
phages in inhibiting the chondrogenic differentiation of MSCs.
Furthermore, we identify M1 polarised subsets as key mediators of
this anti-chondrogenic effect.
Methods
Synovium conditioned medium (SCM) preparation
OA synovial tissue was isolated from six patients (four males,
two females; 63.2 ± 4.2 years) with advanced clinical OA, under-
going total knee replacement at Erasmus MC, University Medical
Center, Rotterdam. OAwas determined based on clinical evaluation
of pain and radiographic changes, including narrowing of the joint
space and osteophyte formation. Ethical approval was granted by
the local ethical committee (MEC2004-322). Synovial tissue was
cut in to pieces of 1e3 mm2 and 200 mg of tissue was cultured in
1 ml of medium composed of Dulbecco's Modiﬁed Eagle's Medium
(DMEM), GlutaMAX™ (Invitrogen, Carlsbad, CA, USA) supple-
mented with 1.5 mg/ml fungizone (Gibco, Carlsbad, CA, USA), 50 mg/
ml gentamycin (Gibco), 1% insulin-transferrin-selenium (BD Bio-
sciences, Erembodegem, Belgium), 25 mg/ml ascorbic acid-2-
phosphate (SigmaeAldrich, St. Louis, MO, USA) 40 mg/ml L-Proline
(SigmaeAldrich) and 1 mM sodium pyruvate (Gibco), referred to as
basic culture medium (BCM). Culture mediumwas refreshed every
24 h, and SCM harvested at day 3 of culture.
Isolation of synovial macrophages and ﬁbroblasts
OA synovial tissue from one patient (female, 59 years) was
digested with collagenase B (Roche, Penzberg, Germany; 1 mg/ml)for 45 min at 37C and gently minced through a 100 mm ﬁlter
(Becton Dickinson, Franklin Lakes, NJ, USA). The resulting cell
suspension was layered on top of 15 ml of Ficoll (FicollePaque™
PLUS, GE Healthcare) and separated by density gradient centrifu-
gation. The interphase layer was removed, washed in BCM and
seeded at 500,000 cells/cm2. Cells were incubated at 37C for
15 min for a macrophage enriched population (MEP). Un-adherent
cells were removed, transferred to a new well and incubated for
120 min to generate a ﬁbroblast enriched population (FEP)24,25.
MEP and FEP conditioned medium (CM) was harvested following
24 h of culture.
11-ﬁbrau stainingwas assessed to conﬁrm the enrichment of each
fraction. 11-ﬁbrau is speciﬁc for a 112-kDa molecule, localised to the
cell surface of human ﬁbroblasts26e28. Isolated synoviocytes cultured
on glass slides were incubated at 37C for 60min for a MEP, and 12 h
for a FEP fraction. Cellswereﬁxed in 70% ethanol for 1 h, blockedwith
10% goat serum (SigmaeAldrich), and incubated for 1 h with mono-
clonal anti-human11-ﬁbrau (Imgenbiosciences,MA,USA;4.2mg/ml).
Slides were incubated for 30minwith a biotinylated anti-mouse link
(Biogenex, fremount, CA, USA), diluted 1:50with phosphate buffered
saline (PBS)/1% BSA/5% human serum (CLB, The Netherlands), and
thereafterwith an alkalinephosphatise-conjugated streptavidin label
(Biogenex) diluted 1:20 with PBS/1% BSA/5% human serum. Slides
were incubatedwithNeuFuchsin,NaNO2,NaphtolAS-MXphosphate,
Di-methylformamidwith levamisole (all SigmaeAldrich) in TRIS-HCl
buffer (0.2M,pH8.5) in thedark for30min.Cellswere counterstained
with haematoxylin and slides mounted utilising VectaMount (Vec-
torlabs, Peterborough, UK).
To obtain synovial macrophages, synoviocytes were separated
based on their expression of the haematopoietic cell marker
CD4529. OA synovial tissue from sixpatients (one male, ﬁve fe-
males; 69.6 ± 7.5 years) was isolated and digested as previously
described. Synoviocytes were incubated with anti-CD45-PE anti-
body (BD Biosciences; diluted 1:100) for 1 h in the dark at 4C,
and labelled with 30 ml of anti-mouse IgG magnetic bead solution
(Miltenyi Biotec, Bergisch Gladbach, Germany) for 30 min in the
dark at 4C. CD45 þ populations were isolated by magnetic
activated cell sorting (MACS, MACS Separation columns LS and
MidiMACS™ Separator, Miltenyi Biotec). Purity of
CD45 þ populations was conﬁrmed by ﬂow cytometry, with
average purity of 95.7% ± 3.1%. Purity of CD45 - populations was
66.5% ± 13.9%, therefore this condition was not used for subse-
quent experiments. CD45 þ cells were seeded at 100,000 cells/
cm2 and cultured in DMEM supplemented with 10% fetal bovine
serum (FBS, Lonza, Verviers, Belgium) for 4 h. Cells were then
washed to remove non-adherent populations and cultured in
BCM for 24 h following which CM was harvested.
Human monocyte isolation and differentiation
Buffy coats were obtained from six healthy male blood donors
(48.5 ± 19.3 years) at the Sanquin blood bank Rotterdam. Two buffy
coats were used per experiment, and peripheral blood mono-
nuclear cells (PBMCs) were isolated by Ficoll density gradient
centrifugation30. PBMCs were labelled with 100 ml of anti-
CD14 þ magnetic bead solution (Miltenyi Biotec) for 20 min in the
dark at 4C and monocytes isolated by MACS.
Monocytes were seeded at 500,000 cells/cm2 and cultured in X-
Vivo™ 15 medium (Lonza) supplemented with 20% FBS, 50 mg/ml
gentamycin and 1.5 mg/ml fungizone. Monocytes were stimulated
with 10 ng/ml IFN-g (PeproTech, Rocky Hill, NJ, USA) & 100 ng/ml
lipopolysaccharide (LPS, SigmaeAldrich) for 72 h for differentiation
towards an M1 or 10 ng/ml IL-4 (PeproTech) for 72 h for an M2
phenotype. Cells were washed and cultured for 24 h in BCM,
following which M1 or M2 CM was harvested.
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Commercially available enzyme-linked immunosorbent assay
(ELISA) kits were used to determine the concentration of IL-6 and
CCL18 in SCM, M1 and M2 CM as per manufacturer's instructions
(R&D systems, Minneapolis, MN, USA).Isolation and culture of human MSCs
MSCs were isolated from heparinised bone marrow aspirates
taken from the iliac crest of a healthy volunteer (male, 35 years) and
a patient with OA undergoing total hip replacement surgery (fe-
male, 77 years) with informed consent. All procedures for collection
of bone marrow have been approved by the Clinical Research
Ethical Committee at University College Hospital, Galway, Ireland
(reference:2/08), the institutional National University of Ireland
Galway Research Ethics Committee (reference:08/May/14) and
local ethical committee of the Erasmus MC, University Medical
Center Rotterdam (MEC2004-142). MSCs were isolated based on
their plastic adherence and expanded in medium consisting of
Minimum Essential Medium alpha (Invitrogen) supplemented with
10% FBS, 1 ng/ml ﬁbroblast growth factor-2 (R&D systems), 25 mg/
ml ascorbic acid-2-phosphate, 1.5 mg/ml fungizone and 50 mg/ml
gentamicin.
For chondrogenic differentiation, MSCs (passage 3) were
encapsulated in 1.2% low viscosity alginate powder (CP Kelco,
Atlanta, GA, USA) dissolved in physiological saline at a density of
4  106 cells/ml. MSC alginate beads were formed by purging
through a 23 gauge needle allowing droplets to fall into 102 mM
CaCl2 solution. Negative control MSC beads were cultured in
incomplete chondrogenic medium (ICM) composed of BCM to
which 0.1 mM Dexamethasone (SigmaeAldrich) was added. For
induction of chondrogenesis, MSC beads were cultured in complete
chondrogenic medium (CCM), composed of ICM with the addition
of 10 ng/ml transforming growth factor (TGF)-b1 (R&D systems).
MSC beads were cultured for 14 days, following whichmediumwas
supplemented with CM from all conditions. 5% SCM, 10% FEP and
MEP CM were added to MSC beads, which were previously iden-
tiﬁed as optimal concentrations. To allow for high variability in cell
number between CD45 þ cell preparations, the lowest cell number
used to generate CM (0.15 mg DNA) was equivalent to a concen-
tration of 50% CM, and all conditions were normalised to this
concentration. To account for high variability in cell number be-
tween M1 and M2 differentiated monocytes, the average cell
number used to generate M1 and M2 CM across all donors, was
equivalent to a concentration of 20% CM (Table I). The effect of SCM
(n¼ 6), FEP andMEP (n¼ 1), CD45þ (n¼ 6), M1 andM2 (n¼ 3) CM
on chondrogenic gene expression, was assessed in experimental
triplicate. Culture was continued for a further 3 days after which
mRNAwas isolated, or 14 days after which samples were harvested
for DNA and glycosaminoglycan (GAG) quantiﬁcations.Table I
Calculation of the percentage of M1 and M2 CM, based on macrophage cell number
(mg DNA)
Donor Condition DNA (mg) % CM
1 M1 1.64 19.95
M2 1.12 29.28
2 M1 1.58 20.65
M2 0.79 41.43
3 M1 3.00 10.88
M2 1.67 19.51
The average cell number used to generate M1 and M2 CM across all donors was
equivalent to a concentration of 20% CM.Quantiﬁcation of DNA content
MSCs were released from alginate after 28 days of culture by
incubation with 55 mM sodium citrate in 20 mM ethyl-
enediaminetetraacetic acid (EDTA), and digested overnight at 60C
with an equal volume of papain solution (250 mg/ml papain in
50 mM EDTA and 5 mM L-cystein (SigmaeAldrich)). Macrophages
were lysed with 500 ml TritonX-100 (SigmaeAldrich) and sonicated
on ice. The DNA content of all samples was determined following
ribonuclease type 3 (12.5 mg/ml, SigmaeAldrich) and heparin
(415U/ml, Leo Pharmaceuticals, Ballerup, Denmark) treatment,
utilising ethidium bromide (5 mg/ml, Gibco). Deoxyribonucleic acid
sodium salt from calf thymus (SigmaeAldrich) was used as a
standard. DNA was quantiﬁed by spectrophotometric detection of
ethidium bromide binding at 340 and 590 nm.
GAG measurement
GAG content of digested MSC alginate samples was determined
spectrophotometrically at 530 and 590 nm after reaction with
dimethylmethylene blue (Polysciences, Valley Road, Warrington,
PA, USA); the pH was lowered to 1.75 for measurements in alginate
samples using chondroitin sulphate from shark cartilage as the
standard (SigmaeAldrich)31,32. The effect of SCM (n ¼ 2) on GAG
content of MSCs was assayed in experimental triplicates.
Gene expression analyses of MSCs and macrophages
MSC alginate beads were dissolved following incubation with
55 mM sodium citrate at 4C. The cell solution was centrifuged at
400g for 8 min, pellet resuspended in 1 ml RNAbee (TelTest,
Friendswood, TX, USA) per 1  106 nuclei and stored at 80C.
350 ml/well of buffer RLT (Qiagen, Hilden, Germany) was used for
direct cell lysis of macrophages. RNA isolationwas performed using
a RNeasy Microkit (Qiagen) and nucleic acid content determined
spectrophotometrically using a NanoDrop ND1000 spectropho-
tometer (Isogen Life Science B.V., The Netherlands) at 260 and
280 nm. cDNA synthesis was performed using RevertAid First
Strand cDNA synthesis Kit (MBI Fermentas, Germany) according to
manufacturer's instructions. Quantitative real-time polymerase
chain reaction (PCR) was performed in 20 mL reactions on cDNA
using CFX96 Touch™ Real-Time PCR Detection System (BIO-RAD,
Hercules, CA, USA) utilising Taqman Universal PCR mastermix
(Applied Biosystems, Foster City, CA, USA) or SybrGreen (Euro-
gentec, Seraing, Belgium). Gene expression of IL-6was assessed as a
marker of M1 and CCL18 and macrophage mannose receptor 1
(MRC1) as markers of M2 macrophages18,33e35. Gene expression
was assessed in differentiatedmacrophages (n¼ 3) in experimental
triplicate. For MSCs, expression of the cartilage-related genes
collagen type II (COL2) and aggrecan (ACAN) were assessed. Primer
pairs were used to determine transcript levels of genes of interest
using settings previously described30,36,37. Gene expression levels
were normalised to Glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) and relative expression calculated using the 2DCT method
(2-(CT gene of interesteCT internal control))38.
Evaluation of macrophage subtypes in synovium
5 mm sections were cut from parafﬁn embedded OA synovial
tissue from 6 donors. Sections were stained for CD86 as a marker of
M1, or CD206 as a marker of M2 macrophages15,18,39. Sections were
deparafﬁnised, washed and heat-mediated antigen retrieval per-
formed. Following blocking with 10% goat serum, sections were
incubated for 1 h with primary antibodies CD206 (Abcam, Cam-
bridge UK; 2.5 mg/ml) or CD86 (Genetex, Irvine, CA, USA; 0.45 mg/
N. Fahy et al. / Osteoarthritis and Cartilage 22 (2014) 1167e11751170ml). Sections were incubated for 30 min with a biotinylated anti-
rabbit Ig link diluted 1:50 with PBS/1%BSA, and thereafter with
an alkaline phosphatase-conjugated streptavidin label diluted 1:50
in PBS/1%BSA. Colour development and processing of sections was
performed as previously described.
Statistical analysis
Normality was veriﬁed using KolmogoroveSmirnov and Sha-
piroeWilk normality tests using SPSS 15.0. Student's t-test was
used to analyse paired data. For paired data that was not normally
distributed, KruskaleWallis test was performed, followed by the
ManneWhitney U test. The false discovery rate was calculated for
each comparison to apply multiple testing correction. For all ana-
lyses, differences were considered statistically signiﬁcant at
P < 0.05.
Results
SCM inhibits MSC chondrogenesis
MSC alginate beads successfully underwent chondrogenesis in
our differentiation system, as indicated by signiﬁcantly increased
COL2 and ACAN gene expression in TGF-b only treated MSC alginate
beads compared to untreated [Fig. 1(A)]. Gene expression levels of
COL2 were signiﬁcantly lower (P ¼ 0.002; average decrease of
75.2% ± 17.3%) in MSCs following treatment with 5% SCM,
compared to MSCs not exposed to SCM [Fig. 1(B)]; this inhibitory
effect was observed following treatment with SCM from all six
donors, ranging from 44.2% to 95.2%. SCM from four of the six do-
nors resulted in decreased expression levels of ACAN (ranging from
49.6% to 75.5%) in SCM-treated beads compared to untreated
(P ¼ 0.27; 41.9% ± 33.6% average decrease) [Fig. 1(B)]. Furthermore,
SCM treatment signiﬁcantly decreased (P ¼ 0.005) GAG content of
MSCs that were cultured for 28 days [Fig. 1(C)].Fig. 1. Osteoarthritic SCM negatively affects chondrogenic differentiation of MSCs. MSC algin
of chondrogenesis. (A) TGF-b stimulation of MSC alginate beads signiﬁcantly increases COL2
triplicates with one MSC donor. (B) Fold change in COL2 and ACAN gene expression levels co
represent the mean ± SD of experimental triplicates. Statistical signiﬁcance was determined
on COL2was signiﬁcant (P ¼ 0.002). (C) GAG content of MSC alginate beads at day 28 of chon
experimental triplicates with SCM from two synovium donors. Statistical signiﬁcance was d
ELISA analysis and quantiﬁcation of IL-6 and CCL18 levels in SCM of six donors with OA.Additionally, the levels of IL-6 and CCL18 in SCMwere quantiﬁed
to evaluate the inﬂammatory state of synovium from each donor.
All donors secreted high levels of IL-6 and lower levels of CCL18,
albeit with high variability between donors [Fig. 1(D)].
Synovial macrophages are orchestrators of the inhibitory effect of
osteoarthritic synovium on MSCs
To investigate whether synovial macrophages play a role in the
detrimental effect of SCM on MSC chondrogenesis, isolated syno-
viocytes were separated to generate ﬁbroblast-enriched (FEP) and
macrophage-enriched (MEP) fractions based on the rapid adhesion
of macrophages to tissue culture plastic. Morphological differences
between cells in both fractions were clear. The MEP fraction dis-
played more cells with a rounded body which was associated with
numerous ﬁlopodia, characteristic of macrophage morphology40.
The FEP fraction contained predominantly elongated cells with
cytoplasmic processes varying in shape and length [Fig. 2(A)].
Immunohistochemical stainings for the ﬁbroblast membrane
marker 11-Fibrau further conﬁrmed cell enrichment of each frac-
tion [Fig. 2(B)]28. COL2 gene expression levels in MSCs were
reduced following treatment with 10% MEP CM. Treatment with
10% FEP CM however, did not negatively impact COL2 expression
[Fig. 2(C)] suggesting that synovial macrophages may be respon-
sible for the anti-chondrogenic effect of OA synovium. To further
investigate this observation, synoviocytes were isolated from six
synovium donors and separated based on their expression of the
haematopoietic cell marker CD4529. CM from CD45 þ populations
reduced COL2 and signiﬁcantly decreased ACAN gene expression
levels (P ¼ 0.01) in MSCs [Fig. 2(D)].
M1 and M2 macrophages are present in end-stage OA synovium
Having identiﬁed a role for synovial macrophages in the inhi-
bition of chondrogenic gene expression in MSCs, we sought toate beads were treated with 5% SCM generated from six OA synovium donors at day 14
and ACAN gene expression (P < 0.001). Values represent the mean ± SD of experimental
mpared to TGF-b stimulated only control following 3 days of 5% SCM treatment. Values
by KruskaleWallis test followed by ManneWhitney U test. The overall inhibitory effect
drogenesis, following 5% SCM treatment for 14 days. Values represent the mean ± SD of
etermined by KruskaleWallis test followed by ManneWhitney U test. * ¼ P < 0.05. (D)
Fig. 2. Synovial macrophages inhibit chondrogenic gene expression in MSCs. MSC alginate beads were treated with 10% CM generated from synovial macrophage enriched (MEP) or
ﬁbroblast enriched (FEP) populations (one synovium donor), and 50% CD45 þ population CM (six synovium donors). (A) Phase contrast images of Haematoxylin-eosin stained MEP
and FEP. Black arrows indicate characteristic macrophage morphology, and white arrows indicate characteristic ﬁbroblast morphology of both fractions. Scale bar indicates 50 mm.
(B) Staining of MEP and FEP for the ﬁbroblast marker 11-ﬁbrau. Scale bar indicates 150 mm. (C) Inhibition of COL2 gene expression in MSCs following stimulation with MEP CM.
Values represent the mean ± SD of experimental triplicates and CM generated from one synovium donor. (D) Inhibition of COL2 and ACAN gene expression in MSCs following
stimulation with 50% CD45 þ population CM. Values represent the mean ± SD of six synovium donors, each assessed in experimental triplicate. Statistical signiﬁcance was
determined by KruskaleWallis test followed by ManneWhitney U test. * ¼ P < 0.05.
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this effect. Immunohistochemical analyses for CD86 as an M1 and
CD206 as an M2 marker conﬁrmed the presence of both subsets in
OA synovium sections from six donors. However, large variation in
the level of expression of each marker between donors was
observed [Fig. 3]. Expression of the M1 marker CD86 was primarilyFig. 3. M1 and M2 macrophages are present in OA synovium. Photomicrographs of OA syno
representatives of paired sections from six donors. Black arrows indicate positive cells, scalocalised to the synovial lining layer in two donors (donor 3&4),
with dispersed expression throughout the sublining region. One
donor (donor 6) contained CD86 expressing cells predominantly in
the sublining layer. Conversely, three donors (donor 1, 2 & 5) did
not express this marker. We detected expression of the M2 marker
CD206 in four donors (donor 2, 3, 4 & 5), throughout the synovialvium stained with anti-CD86, anti-CD206 or IgG isotype control antibody. Images are
le bare indicates 300 mm.
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expressing cells localised to the sublining region (donor 1 & 6).
M1 polarised macrophages negatively impact MSC chondrogenesis
Medium conditioned byM1 differentiatedmonocytes contained
signiﬁcantly higher levels of the M1-associated cytokine IL-6
(P ¼ 0.039), but low levels of the M2-associated chemokine
CCL18. Conversely, medium conditioned by M2 differentiated
monocytes did not contain IL-6, but CCL18 was signiﬁcantly
(P ¼ 0.0278) increased [Fig. 4(B)]. Moreover, differentiated mono-
cytes exhibited IL6, CCL18 andMRC1 gene expression proﬁles of M1
and M2 polarised cells [Fig. 4(A)]. This characteristic pattern of
cytokine and gene expression was observed with each of the three
biological replicates. Treatment of chondrogenicMSCs with 20%M1
CM signiﬁcantly inhibited COL2 (P < 0.001) and ACAN (P < 0.001)
gene expression compared to untreated chondrogenic MSCsFig. 4. M1, and not M2, macrophages inhibit chondrogenesis of MSCs. Primary monocytes (
stimulation with IFN-g & LPS or IL-4 for 3 days. (A) Gene expression of the M1 marker IL-
represent the mean ± SD of three biological replicates, statistical signiﬁcance was determine
and CCL18 levels in M1 and M2 macrophages. Values represent the mean ± SD of three bi
* ¼ P < 0.05. (C) Gene expression of COL2 and ACAN following stimulation of MSC beads with
triplicates, each assayed in experimental triplicate. Statistical signiﬁcance was determin
*** ¼ P < 0.001.(80% ± 14.1% and 86.8% ± 11.5% decrease, respectively) [Fig. 4(C)].
This inhibitory effect was observed with M1 CM from each bio-
logical replicate (ranging from 63.8% to 89.7% for COL2, and 73.6% to
94.5% for ACAN). We did not observe any signiﬁcant difference in
COL2 gene expression levels between MSCs treated with 20% M2
CM and untreated MSCs (P ¼ 0.124). However, treatment with 20%
M2 CM did signiﬁcantly reduce ACAN gene expression (P ¼ 0.002;
average decrease of 27.3% ± 9.9%, ranging from 17.2% to 36.9%).
Discussion
The inhibitory effect of factors secreted by OA synovium onMSC
chondrogenesis has been previously reported, however, the exact
mechanism responsible for this effect has yet to be elucidated3,4. In
this study, we report that synovial macrophages isolated from OA
synovium orchestrate the negative impact of OA synovium on MSC
chondrogenesis. Furthermore, we show that M1 polarised subsets3 biological replicates) were differentiated towards an M1 or M2 phenotype following
6 and the M2 markers CCL18 and MRC1 in M1 or M2 stimulated macrophages. Values
d by a paired Student's t-test, * ¼ P < 0.05. (B) ELISA analysis and quantiﬁcation of IL-6
ological replicates, statistical signiﬁcance was determined by a paired Student's t-test,
20% M1 or M2 CM for 3 days. Values represent the mean ± SD of macrophage biological
ed by a KruskaleWallis test followed by ManneWhitney U test, ** ¼ P < 0.005,
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implicate M1 synovial macrophages as key regulators of the anti-
chondrogenic effect of OA synovium.
Pro-inﬂammatory mediator production by inﬂamed synovium
is a feature of OA pathology, postulated to drive destructive events
in neighbouring chondrocytes5,9. Synovial macrophages play a key
role in the production of such factors, however, little is known
regarding the effect of macrophage subsets on MSC chondro-
genesis. We conﬁrmed the presence of different macrophage sub-
sets by CD86 and CD206 immunohistochemical staining on OA
synovium sections. In addition we have analysed secretion of an
inﬂammatory cytokine IL6 and an anti-inﬂammatory cytokine
CCL18. Remarkably, SCM from donor 1 contained less IL-6 and
CCL18 than SCM from other donors, and failed to reduce COL2 and
ACAN gene expression in MSCs. These ﬁndings may suggest that the
anti-chondrogenic effect of OA synovium is dependent on its in-
ﬂammatory status. Interestingly, Gierman et al. have detected
comparable expression levels of inﬂammatory mediators by end-
stage OA and normal synovial tissue, and an effect of OA syno-
vium on GAG release from cartilage explants was not observed41.
Previous studies have demonstrated that OA synovium does not
affect GAG release but inhibits GAG synthesis in cultured osteoar-
thritic cartilage explants7. We have observed an inhibitory effect of
OA SCM on the expression of ACAN and COL2 in MSCs during
chondrogenic differentiation, and signiﬁcantly reduced GAG con-
tent compared to MSCs not exposed to SCM. In this system, as in
cartilage explants, end stage OA synovium may not directly induce
cartilage degradation and GAG release, but adversely affect GAG
production.
A mixed expression pattern of M1 and M2 macrophages was
previously detected in the synovium of patients with OA, and
macrophages localised to the synovial lining preferentially
expressed markers of M2 polarised cells42. However, we detected
similar levels of M1 and M2 markers localised to the lining layer
in end-stage OA synovial tissue. M1 and M2 CM, prepared from
human blood derived monocytes polarised to an M1 or M2
phenotype, were used as a model system to address the effect of
both subsets on MSC chondrogenesis. The signiﬁcant difference in
protein and gene expression of IL6 and CCL18 between M1 and
M2 cells, validate the use of M1 and M2 CM as a model system for
macrophage subtypes. Corresponding with OA SCM, M1 CM
signiﬁcantly decreased COL2 and ACAN gene expression of MSCs,
where inhibition of COL2 was not observed following treatment
with M2 CM. Although M2 CM treatment inhibited ACAN gene
expression, this inhibitory effect was less than the effect observed
with M1 CM. Interestingly, M1 polarised macrophages have been
reported to inhibit the proliferation and viability of MSCs in vitro;
this effect was not observed with cells and mediators of the M2
subset43. However, we did not observe any difference in DNA
content between M1 CM, M2 CM or untreated chondrogenic
MSCs, suggesting that M1 polarised cells elicit an unfavourable
effect in our system by directly impacting chondrogenic gene
expression.
For proof of principle that synovial macrophages are responsible
for the inhibitory effect of OA synovium, the effect of CM from sy-
novial ﬁbroblast and macrophage enriched populations on chon-
drogenesis was assessed. Our initial ﬁndings suggest that synovial
macrophages are primary mediators of the anti-chondrogenic ef-
fect. Given the unreﬁned nature of this technique, we sought to
isolate synovial macrophages based on their expression of CD4529.
CD45 þ CM negatively impacted chondrogenic gene expression by
MSCs. Although we achieved 95.7% purity of CD45 þ populations,
purity of CD45- populations was 66.5% and therefore not utilised
for our experiments. Given the technically challenging nature of
this technique, further optimisation may be required to isolate purepopulations and fully clarify the contribution of synovial ﬁbroblasts
to the inhibitory effect of OA synovium. Advanced OA synovium has
been reported to contain CD45þ natural killer and Tcell inﬁltrating
populations, and we cannot rule out the presence of these pop-
ulations in our system44. However, we believe that the removal of
non-adherent cells prior to conditioning of medium may have
depleted such leucocyte populations which do not adhere during
culture45.
An MSC alginate bead system was utilised to assess the chon-
drogenic differentiation of MSCs, and the suitability of this system
has been previously reported46. Randeau et al. observed compara-
ble levels of proteoglycan production and gene expression of COL1,
COL2 and COL10 between chondrogenically differentiating MSCs
cultured in alginate beads and pellets. In previous studies we have
used pellet cultures to investigate the effect of SCM47,48, and have
conﬁrmed that the effect on COL2 and ACAN gene expression is
similar in alginate and pellet cultures. Furthermore, MSCs in algi-
nate have formed cartilage matrix in vivo49,50. Together, these
ﬁndings validate the use of the alginate system for MSC
chondrogenesis.
Our study has some limitations. Firstly, MSCs from one donor
were used per experiment to analyse the effect of SCM, FEP, MEP,
CD45þ, M1 or M2 CM on chondrogenesis. However, each exper-
iment demonstrated a clear inhibitory effect. Moreover, in pre-
vious experiments we observed a strong negative effect of OA-
SCM, pooled from seven donors, on the chondrogenic differenti-
ation of different MSC donors in pellet culture47,48. Given that the
negative impact of SCM on MSC chondrogenesis is consistent, we
believe that the use of one MSC donor per experiment is sufﬁ-
cient. A second limitation includes the restriction of our analyses
to IL-6 and CCL18 as indicators of the inﬂammatory proﬁle of
synovium from each donor. Although IL-6 has been previously
described to be abundantly present in OA SCM, and in vitro cell
cultures have associated these cytokines with M1 and M2 mac-
rophages respectively, caution should be applied when making
any association between the presence of these factors in OA SCM
and synovial macrophages7. Furthermore, this is an in vitro study
using differentiated human monocytes to model the effect of
synovial tissue resident macrophages on MSC chondrogenesis.
From our data, we have observed an inhibitory effect of M1
differentiated macrophages, however further analysis is required
to clearly elucidate a role of M1 polarised synovial tissue
macrophages.
In summary, we have conﬁrmed the inhibitory effect of OA SCM
on the chondrogenic differentiation of MSCs and have identiﬁed
M1 polarised macrophages as potential mediators of this anti-
chondrogenic effect. We propose that modulation of synovial
macrophage phenotype towards an anti-inﬂammatory state or
attenuation of M1 mediators may be of vital importance for the
development of efﬁcient MSC-based cartilage regeneration
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